Are two‐stage hepatectomies associated with more complications than one‐stage procedures?  by Schadde, Erik et al.
ORIGINAL ARTICLE
Are two-stage hepatectomies associated with more complications
than one-stage procedures?
Erik Schadde1,2, Ksenija Slankamenac1,2, Stefan Breitenstein1, Mickael Lesurtel1, Michelle De Oliveira1,
Beatrice Beck-Schimmer2, Philipp Dutkowski1 & Pierre-Alain Clavien1
Swiss HPB Center, Departments of 1Surgery and 2Anesthesiology, University of Zurich Hospital, Switzerland
Abstract
Background: Two-stage liver resections with portal vein occlusion have become standard in patients
with low volume future liver remnants. Whether they are associated with more complications is unclear.
The aim of this study was to compare complications of one- and two-stage resections in a retrospective
study.
Methods: Patients with two-stage right liver resections with a previous portal vein occlusion were
compared with patients with one-stage right liver resections between 2002 and 2010. Primary endpoints
were the incidence of complications by severity. Secondary endpoints were mortality, post-operative liver-
and kidney function tests, length of hospitalization and transfusion events. Logistic and linear regression
analyses were performed to adjust for confounders.
Results: The groups were comparable except for right trisectionectomies, pre-operative chemotherapy
and underlying liver disease. Overall complications occurred in 25 out of 35 patients with two-stage and
106 out of 163 in one-stage procedures. Severe complications were observed in 47 out of 163 patients
versus 9 out of 35 patients, respectively. Two-stage procedures had no increased adjusted risk for
complications [relative risk (RR) 0.9, P = 0.79]. Mortality (5.7% versus 3.7%) and post-operative liver
failure rates (2.9% versus 3.1%) were low. Secondary endpoints showed no adjusted differences in risk.
Conclusion: This study suggests that liver resections in two stages are not associated with more
post-operative complications than one-stage resections. These results should support the adoption of
two-stage liver resections in selected patients.
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Introduction
A two-stage liver resection was developed more than 10 years ago
in patients with extensive hepatic tumour load localized in the
liver to achieve complete (R0) resections. The aim was to prevent
too extensive resection with one-stage surgery only, which might
leave an insufficient remnant liver and a risk of post-operative
liver failure and death.1 Subsequently, a number of modifications
were described such as portal vein embolization as the first stage,
after the first stage2 or portal vein ligation during the initial
operation, both aiming at an increase of the volume of the future
liver remnant (FLR) prior to the second operation.3,4 The FLR is
the volume of liver remaining after a resection and is usually
determined in absolute volume units by volumetry or in per cent
of either the volumetric total liver volume (FLR) or in per cent of
the standardized liver volume based on body surface area and
weight (sFLR).5 Single-centre non-comparative studies focusing
on colorectal cancer metastases have reported completion of the
procedures in two stages in patients enrolled in stage one in the
range of 69% to 81%. Disease-free and overall survival were com-
parable to one-stage resections for hepatic colorectal cancer
metastases in patients with a lesser tumour load.6 The median
interval between the hepatic resections in the reported series was
between 6 weeks and 4.5 months.1,2,7–9 In the majority of the
strategies used, the major liver resection is performed during
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the second stage, and thus associated with a longer operative time,
more blood loss and more complications, as well as longer hospi-
tal stay, than the smaller liver resections performed during the first
operation.2,6,8 The difference is likewise related to the more exten-
sive liver surgery, but other factors such as the impact of operating
in the same field for a second time may also contribute to the
higher complication rate. On the other hand, portal vein manipu-
lations and two-stage approaches are generally chosen to make
right hepatectomies and right trisectionectomies safer by increas-
ing the volume of the FLR in patients in which the FLR is judged
too small with an increasing risk of post-operative liver failure.
Therefore, major liver resections performed in two stages might
actually be safer.
The goal of this study was to examine complications and
resource utilization of major liver resections performed in two
stages as compared with one-stage procedures. As the majority of
procedures performed in two stages are on the right side, the
analysis was limited to right hepatectomies or trisectionectomies.
Methods
Study population and design
Data were analysed from a prospectively collected liver surgery
database of hepatectomies, performed between 2002 and 2010
in a single tertiary care centre [Swiss Hepato-Pancreatico-Biliary
(HPB) Centre, University Hospital Zurich, Switzerland], thereby
identifying right hepatectomies and right trisectionectomies.
Patients with combined liver and extrahepatic resections were
excluded. Of the remaining cases, those performed in one stage
were segregated from those carried out in two stages with portal
vein ligation in stage one. The study was approved by the institu-
tional review board for human studies at the University Hospital
Zurich (KEK-ZH-Nr. 2012-0386).
Surgical procedure
The one-stage procedures were performed in livers with a volume
of >30% of future liver remnant/total liver volume (FLR/TLV).
The clamp crush technique for parenchymal transection and
selective inflow occlusion (Pringle manoeuvre) were used as nec-
essary. The two-stage procedures were chosen for livers with a
FLR/TLV < 30% using a combination of portal vein ligation with
cleaning of the future liver remnant in stage one. The second
major resection followed once the FLR/TLV reached at least 30%
according to a previously published approach.4 Volumes of sFLR
were calculated by subtracting the resected specimen weight from
the standardized total liver volume based on weight and body
surface area as described by Vauthey et al.5
Endpoints
The primary endpoint was post-operative complications. This
parameter was assessed using the Clavien–Dindo classification.9
Complications >IIIA were considered as severe complications
according to this previous publication.10 Secondary endpoints
were defined as follows: mortality during hospitalization (grade V
Clavien–Dindo), liver failure as defined by the ‘50-50’ criteria as
assessed by bilirubin levels and prothrombin time at day 5,11
as well as post-operative peak levels of aspartate transaminase
(AST), alanine transaminase (ALT), bilirubin and creatinine,
intra-operative blood loss and the percentage of patients under-
going intra-operative blood transfusions (packed red blood cells
and fresh frozen plasma) by review of anaesthesia records, length
of stay on a special care unit and length of hospitalization.
Statistical analysis
The distribution of variables was analysed using means and
standard deviation (SD) for normally distributed, and median
and interquartile ranges (IQR) for non-normally distributed
data. Data were tested for normality using the Kolmogorov–
Smirnov test and performed quantile–quantile plots of dependent
variables.
The primary endpoint (the percentage of patients with overall
and severe complications) was compared between the two groups
using univariate logistic regression, and in the main analysis, a
multivariable logistic regression model with complications as the
dependent, and group allocation as the independent variable.
Potential confounders for which we adjusted in the multivariate
logistic regression analysis were gender (male/female), pre-
operative chemotherapy (yes/no), the American Society of
Anesthesiologists (ASA) physical status classification (2/<2),
macrovesicular liver steatosis (<30%, >30%), liver fibrosis (yes/
no), baseline ALT and AST, pre-operative bilirubin and creatinine
levels, extent of resection by description of a right trisectionec-
tomy or right hepatectomy in the operative reports and blood loss
and intra-operative transfusions.
This study did not include enough patients for a multivariate
analysis for the endpoints mortality during hospitalization,
90-day mortality and liver failure according to the ‘50/50’ criteria.
Uni- and multivariate linear regression analyses were per-
formed for further secondary endpoints such as peak levels of
transaminases, total bilirubin and creatinine after surgery, blood
loss and intra-operative blood transfusions, length of stay on a
special care unit and hospital stay. Data were reported as point
estimates, 95% confidence intervals (CI) and P-values (0.05
considered as significant).
Data were analysed using the statistical program STATA
(Version 11; Stata Corp., College Station, TX, USA).
Results
Figure 1 represents a flow sheet of the patient population identi-
fied in the database. One hundred and sixty-three one-stage pro-
cedures were compared with 35 operations performed in two
stages.
Patient characteristics are shown in Table 1. Patients undergo-
ing two-stage resections had a higher ASA score, higher Charlson
index and more metastatic liver tumours than those undergoing
one-stage resections. Along with this there was more use of
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chemotherapy prior to resections in two-stage resections. The
presence of >30% steatosis or fibrosis was more frequent in the
two-stage resections. No differences were found in the size of sFLR
at the time of resection.
Intra-operative parameters are presented in Table 2. There were
more trisectionectomies in the two-stage group.
Uncorrected post-operative outcomes are compared in Table 3
(univariate analysis) and relative risks (RR) for outcome end-
points in the multivariate regression model in Table 4. Taking
into account the possible confounders, the two-stage group was
not at risk for more overall complications [RR 0.9, with a 95%
confidence interval (CI) 0.36–2.17, P = 0.79] or severe compli-
cations (RR 0.5, 95% CI 0.17–1.3, P = 0.14). The incidence of
liver failure by the ‘50/50’ criteria could not be statistically evalu-
ated because of the small number of events (less than 5).
Mortality during hospitalization (=Grade V complication) and
30-day mortality could also not be compared owing to the small
number of events. There was a trend towards a higher 90-day
mortality in the two-stage group in the model [adjusted odds
ratio (OR) 3.7, P = 0.06]. The two-stage group was not at risk
for increased levels of post-operative transaminases, bilirubin
or creatinine, or for blood loss or blood transfusions in the mul-
tivariate model.
A subgroup analysis of outcomes for patients undergoing tri-
sectionectomies (n = 70) is shown in Table 5. Nomortalities in the
procedures performed in the context of two-stage operations
could be observed. As a result of low numbers, a multivariate
regression model could not be performed.
Discussion
This study suggests that major resections in two stages with pre-
vious resections and portal vein embolization or ligation with the
intent to induce future liver remnant volumetric growth are not
associated with a higher degree of overall or severe post-operative
complications than can be observed in one-stage major liver
resections. The number of mortalities in both groups is within the
expected range for complex major liver surgery.12 These results
compare with previously published data that have demonstrated a
mortality of 0–9% and an overall complication rate of 26% to
59% after two-stage liver resections.2,8,9,13 The 65–71% incidence
of overall complications in this series is 10% higher than in past
studies. This might be as a result of the prospectively collected
complications database in Zurich with several levels of quality
control. It has been demonstrated in the past that clinical data
collection may lead to underreporting of complications.14
One of the two mortalities after the two-stage resections in this
series might have been because of a small sFLR of 40%. The
second patient had a sFLR of 47% and died because of a bile leak
and progressive sepsis. Five of the six mortalities after one-stage
resections were reported in the medical documentation to be as a
result of post-operative liver failure, one was related to a post-
operative stroke event. However, in no case was the size of sFLR
less than 40%.
A subgroup analysis for extended right trisectionectomies
showed that there was nomortality in 19 procedures performed as
a second stage compared with 6% of one-stage right trisectionec-
tomies. The incidence of severe complications also appeared
reduced (Table 5). As a result of the low incidence of events, a
multivariate analysis for this subgroup could not be performed.
However, larger series of right trisectionectomies reported peri-
operative mortalities between 6% and 12%15,16
None of the clinical markers suggesting a higher risk such as
increased post-operative creatinine or bilirubin values, and the
duration of special care unit and hospital stay were the same. Also
blood loss and transfusions were not significantly increased in the
two-stage resection group, once the analysis was corrected for
possible confounders. It could be postulated that portal vein
manipulation makes major liver resections safer by increasing the
size of the FLR outweighing the potential risks of liver surgery
after previous portal vein manipulation.
This study is timely because of the recently presenteddata of new
approaches to two-stage resections such as the Associating Liver
Partition with Portal vein Ligation for Staged Hepatectomy
(ALPPS) approach.17–19 In this operation, rapid hypertrophy of the
volume of FLR is induced by parenchymal transection with portal
vein ligation as a first stage. Stage two is then performed in rapid
succession 1 or 2 weeks after stage one. The relatively high overall
mortality rate of 10% or more reported by the pioneers and other
early experience of this approach17 has led to a discussion about the
clinical safety to the new rapid hypertrophy approach, as compared
with the traditional approach of two-stage hepatectomies. From
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Figure 1 Flow chart of our liver resection database to compare a
cohort undergoing right liver resections in one stage with a cohort
undergoing right liver resections as a second stage of a two-stage
procedure
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the data presented here, it appears that the second stage, at least in
traditional two-stage strategies, is comparable in risk to standard
major right liver resections.However, careful prospectivemonitor-
ing using validated systems for recording complications such as the
Clavien–Dindo classification shows that severe complications in
right liver resections occur in 25–28%. The incidence for severe
complications (>IIIA) in liver resections overall including a minor
resection is 24% in previous studies using the samemethodology.20
Table 1 Characteristics of patients undergoing right liver resections either in one stage or as a second stage of a two-stage procedure
Right liver resection
One-stage procedure
n = 163
Two-stage procedure
n = 35
P-value
Age (years) 57 (46–67) 59 (48–64) 0.82
Gender male/female 86/77 22/13 0.28
BMI (kg/m2) 24 (22–27) 23.4 (21.1–28) 0.72
Charlson Index 6 (2–9) 8 (6–9) <0.001
ASA score 2 (2–2) 2 (2–3) 0.036
– 2 133 26
– >2 30 9 0.32
Malignant disease 125 31 0.24
Pre-operative chemotherapy 64 21 0.025
Liver tumour 0.008
– None 7 0
– Primary 74 9
– Secondary 82 26
Portal vein embolization/portal vein ligation 0 9/26 –
sFLR (%) 47% (19–69%) 47% (19–64%) 0.96
Liver cirrhosis 8 2 0.85
Liver steatosis 70 16 0.79
– 30% 23 11 0.006
Liver fibrosis 33 10 0.29
AST preoperative (U/l) 30.5 (23–41) 37.5 (28–47) 0.037
ALT preoperative (U/l) 29 (19–45) 35 (25–60) 0.07
Bilirubin pre-operative (mmol/l) 9 (6–13) 8.5 (6–11) 0.36
Creatinine pre-operative (mmol/l) 77 (67–89) 74 (65–79) 0.24
All results are presented in median (interquartile range).
ASA, American Society of Anesthesiologists score; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index; sFLR,
standardized future liver remnant at the time of resection (weight of standardized total liver volume minus weight of the resected specimen).
Table 2 Intra-operative parameters of patients undergoing right liver resections either in one stage or as a second stage of a two-stage
procedure
Right liver resection
One-stage procedure
n = 163
Two-stage procedure
n = 35
P-value
Trisectionectomy 51 19 0.01
Surgery time (min) 310 (260–370) 320 (300–405) 0.16
Pringle ( no. of patients) 139 27 0.45
– Pringle time (min) 30 (28–37) 30 (27–38) 0.18
Blood loss (ml) 500 (300–800) 600 (400–1000) 0.07
Red blood cell transfusion 18 7 0.19
Fresh frozen plasma transfusion 6 2 0.63
All results are presented in median and interquartile range.
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A limitation of the current study is that the groups differ in
certain characteristics. The results were therefore adjusted for pos-
sible confounders to increase the validity of the results. More
pre-operative chemotherapy might put the two-stage hepatec-
tomy cohort at a disadvantage. There were also more fibrotic livers
and more livers with macrosteatosis over 30% selected for the
two-stage approach, which also potentially puts the two-stage
hepatectomy patients at a disadvantage. The second stage of the
two-stage hepatectomy cohort also encompassed more right tri-
sectionectomies and the need for increased use of blood transfu-
sions, which might all be direct and indirect markers for more
extensive resections.
The association of the size of FLR to post-operative outcomes
has been demonstrated in several studies in the past; however, the
cut-off of safer liver surgery based on volumetry and histological
changes remains controversial.4,15,21–24 Liver weight, recorded in
pathology reports of a resected specimen, were used and sub-
tracted from the standardized total liver volume to estimate the
sFLR at the time of resection. Calculations demonstrate that sFLR
Table 3 Post-operative outcome of patients undergoing a right liver
resection either in one stage or as a second stage of a two-stage
procedure
Right liver resection
One-stage
procedure
n = 163
Two-stage
procedure
n = 35
Post-operative complications
overalla (incl. mortality during
hospitalization)
106 25
Post-operative complicationsa
– None 57 10
– Grade I 31 7
– Grade II 28 9
– Grade IIIA 22 3
– Grade IIIB 9 0
– Grade IVA 7 2
– Grade IVB 3 2
– Grade V (=mortality during
hospitalization)
6 2
Severe complications IIIAa 47 9
Post-operative liver failure b 5 1
30 days mortality 5 0
90 days mortality 9 5
AST peak (U/l) 505 (334–807) 543 (370–986)
ALT peak (U/l) 461 (306–737) 476 (293–1030)
Bilirubin peak (mmol/l) 45 (33–63) 38 (20–63)
Creatinine peak (mmol/l) 82 (68–96) 79 (69–107)
Length of hospital stay (days) 12 (10–15) 12 (11–22)
Length of special care unit
stay (days)
1 (1–2) 1 (1–1)
All results are presented in median and interquartile range.25
aComplication classification according to the Clavien–Dindo classifica-
tion system.
‘Complications  III A’ includes mortality during hospitalization.
bPost-operative liver failure as defined by the ‘50-50’ criteria.
AST, aspartate aminotransferase; ALT, alanine aminotransferase.
Table 4 Primary endpoint complications as well as secondary end-
points after liver resection as the second stage of a two-stage
hepatectomy compared with resection in one stage expressed as an
odds ratio or difference between values, adjusted in a multivariate
regression model
Odds ratio or difference for two-stage
hepatectomy versus one-stage
hepatectomy in multivariate regression model
Unadjusted odds ratio
(95% CI, P-value)
Adjusted odds ratio
(95% CI, P-value)
Post-operative
complications
overalla
1.3
(0.6–3.0, P = 0.47)
0.9
(0.36–2.17, P = 0.79)
Severe
complications
 IIIAa
0.9
(0.37–1.96, P = 0.71)
0.5
(0.17–1.30, P = 0.14)
Post-operative
liver failureb
– –
Mortality during
hospitalization
(Grade V)b
– –
30 day mortalityb – –
90 day mortality 2.8
(0.9–9.0, P = 0.079)
3.7
(0.9–15.2, P = 0.066)
Unadjusted difference
(95% CI, P-value)
Adjusted difference
(95% CI, P-value)
AST peak (U/l) 86.6
(-89.8–263.1, P = 0.33)
-11.4
(-204.5–181.6, P = 0.91)
ALT peak (U/l) -1.54
(-171.4–174.5, P = 0.99)
-78.0
(-269.0–113.0, P = 0.42)
Bilirubin peak
(mmol/l)
5.3
(-19.5–30.1, P = 0.68)
11.8
(-16.8–40.4, P = 0.42)
Creatinine peak
(mmol/l)
9.4
(-6.8–25.6, P = 0.25)
3.6
(-13.9–21.2, P = 0.68)
Length of
hospital stay
(days)
4.1
(1.2–6.9, P = 0.005)
1.9
(-1.0–4.9, P = 0.20)
Special care unit
stay (days)
0.86
(-0.8–2.5, P = 0.30)
0.3
(-1.4–2.1, P = 0.70)
Blood loss (ml) 51.0
(-254.9–357.0, P = 0.74)
-54.7
(-395.3–285.8, P = 0.75)
Blood transfusion
(%)
2.0
(0.77 -5.27, P = 0.15)
2.3
(0.42–12.98, P = 0.34)
All results are presented in median (interquartile range).
All results are adjusted for possible confounders such as gender, pre-
operative chemotherapy (no/yes), ASA score (2/ > 2), liver steatosis
(<30%/30%), liver fibrosis (no/yes), baseline ALT/AST and bilirubin
level, trisectionectomy, blood loss.
ASA, American Society of Anesthesiologists score; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase.
aComplication classification according to the Clavien–Dindo classifica-
tion system.
bLess than five events: therefore no statistical calculation was performed.
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volumes between the two groups were similar and ranged from
19% to over 60% in both groups, presumably as a result of portal
vein manipulation prior to resection. None of the mortalities
occurred in a patient with a sFLR < 40%.
Lastly, complications were chosen as a global outcome includ-
ing mortality as the small number of patients with two-stage
resections, even in large centres, makes it difficult to choose mor-
tality or liver failure, as a primary endpoint. Prospective studies
will have to be performed to evaluate the two-stage resections with
portal vein ligation especially given the recent technical innova-
tions such as the ALPPS procedure.
In conclusion, evidence is provided that two-stage liver resec-
tions with portal vein occlusion are not associated with a higher
peri-operative risk compared with one-stage liver resections in
spite of the high-risk population, in which they are used.
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